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Abstract
Achromatopsia is a genetic disorder of cones, and one of the most common forms is a channelopathy
caused by mutations in the β-subunit, CNGB3, of the cone cyclic nucleotide-gated (CNG) channel.
Recombinant adeno-associated virus of serotype 5 (rAAV5)-mediated gene transfer of human CNGB3
cDNA to mutant dog cones results in functional and structural rescue in dogs <0.5 years of age, but
treatment is minimally effective in dogs >1 year. We now test a new therapeutic concept by combining
gene therapy with the administration of ciliary neurotrophic factor (CNTF). Intravitreal CNTF causes
transient dedifferentiation of photoreceptors, a process called deconstruction, whereby visual cells
become immature with short outer segments, and decreased retinal function and gene expression that
subsequently return to normal. Cone function was successfully rescued in all mutant dogs treated
between 14 and 42 months of age with this strategy. CNTF-mediated deconstruction and regeneration of
the photoreceptor outer segments prepares the mutant cones optimally for gene augmentation therapy.
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Transient Photoreceptor Deconstruction by CNTF
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in Late Stage CNGB3-Achromatopsia
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Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA; 3Department of Ophthalmology and
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Achromatopsia is a genetic disorder of cones, and one of
the most common forms is a channelopathy caused by
mutations in the β-subunit, CNGB3, of the cone cyclic
nucleotide-gated (CNG) channel. Recombinant adenoassociated virus of serotype 5 (rAAV5)-mediated gene
transfer of human CNGB3 cDNA to mutant dog cones
results in functional and structural rescue in dogs <0.5
years of age, but treatment is minimally effective in dogs
>1 year. We now test a new therapeutic concept by
combining gene therapy with the administration of ciliary neurotrophic factor (CNTF). Intravitreal CNTF causes
transient dedifferentiation of photoreceptors, a process
called deconstruction, whereby visual cells become
immature with short outer segments, and decreased
retinal function and gene expression that subsequently
return to normal. Cone function was successfully rescued
in all mutant dogs treated between 14 and 42 months
of age with this strategy. CNTF-mediated deconstruction
and regeneration of the photoreceptor outer segments
prepares the mutant cones optimally for gene augmentation therapy.
Received 8 August 2012; accepted 3 March 2013; advance online
publication 9 April 2013. doi:10.1038/mt.2013.50

INTRODUCTION

Recent breakthroughs in retinal gene therapy provide hope of
effective treatments for inherited blinding disorders once considered incurable. For example, Leber congenital amaurosis, caused
by loss of function of the RPE65 gene, is being successfully treated
by delivery of RPE65 to the retinal pigment epithelium via recombinant adeno-associated virus (rAAV)-based vectors.1–5 This
promising therapy evolved from proof of concept studies using
rAAV-based viral vectors that established efficacy and preliminary
safety in directing gene expression to the retinal pigment epithelium in dogs, mice, and primates.6–9 The same technology is now

used successfully to treat primary photoreceptor disorders in animal models, among which include achromatopsia and different
forms of retinitis pigmentosa.10–18
Gene augmentation therapy, however, has been marginally
effective or ineffective when the photoreceptor degeneration starts
too early or progresses too rapidly.19–21 To circumvent this problem, rAAV vectors of different serotypes have been developed,
e.g., rAAV8 versus rAAV5, with tyrosine-capsid mutations and/or
self-complementary variants that minimize the interval between
transduction and transgene expressions.18,22–24
An intermediate situation occurs when the degeneration rate is
slow, but functional and/or structural rescue of the photoreceptor
disease is not possible. Such is the case in CNGB3-achromatopsia,
a channelopathy affecting cone photoreceptors in humans,25,26
dogs,27 and mice,28 where treatment outcomes were age and disease stage dependent.10,14 In dogs, we found that successful restoration of cone function decreased from 11 of 14 eyes treated at
<0.5 year of age, to 1 of 3 in those >1 year.10 The decreased rescue
of cone function could not be explained by the absence of cones or
the lack of CNGB3 transgene expression. As successfully treated
cones showed localization of cyclic nucleotide-gated (CNG) channel and G-protein expression in the outer segments, in contrast to
their absence in treated but non-functional retinas, we suspected
that the failure possibly resulted from the improper reassembly of
the components of the phototransduction machinery when retinas were treated at later stages of disease.10
In this study, we tested the hypothesis that regenerating the
older CNGB3-mutant cone outer segments with ciliary neurotrophic factor (CNTF) could enable restoration of cone phototransduction following gene augmentation therapy with the
rAAV5-PR2.1-hCNGB3 therapeutic vector. CNTF is one of the
most studied neurotrophic factors in retinal degenerative disorders and has profound effects on the retina and photoreceptors.29
When administered intravitreally, the outer segments shorten significantly before regrowing, and photoreceptor gene expression is
transiently downregulated.30 Because the changes are reversible,
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and the treated photoreceptors transiently become more immature, we have termed the process transient photoreceptor deconstruction.31,32 Recent studies indicate that CNTF also promotes
cone outer segment regeneration in the degenerating rat retina.33
Our present results clearly show that intravitreal injection
of human recombinant CNTF one week before treatment with
rAAV5-PR2.1-hCNGB3 in CNGB3-mutant dogs >1 year of age
permitted restoration of cone function in all treated eyes, whereas
no functional recovery was found in control eyes pretreated with
phosphate-buffered saline (PBS). Our results provide proof of concept for a novel combination therapy to facilitate restoration of cone
function in future clinical application. They also provide an insight
into the mechanism that mediates the assembly of CNG channels,
and their targeting to the cone outer segments in the disease.

RESULTS
Subretinal rAAV5-PR2.1-hCNGB3 transduces older
mutant cones but fails to restore function

Subretinal administration of the therapeutic rAAV serotype 5
vector with hCNGB3 regulated by the full-length human red cone
opsin promoter, rAAV5-PR2.1-hCNGB3, resulted in cone functional rescue in only 1 of 10 treated eyes of mutant dogs >1 year

of age (Table 1). This finding was the same in dogs with either
the genomic deletion or D262N missense mutation,27 and was
observed with treatment by subretinal injection alone (n = 3; prior
study),10 or one week following intravitreal PBS injection (n = 7;
Figure 1a). The failure of functional rescue was not due to lack of
cones. Retinal flat mounts at 1 year of age showed an ~25% average
loss of both L/M- and S-cones (Figure 2a). Loss is greater in the
inferior and nasal quadrants, and cones are best preserved in the
area centralis region that was targeted for treatment (Figure 2a).34
Over a 7-year time period, we find a continuous, but slow loss
of cones. Even in older animals, however, some intact cones with
shortened outer segments remain, confirming previous observations (Figure 2b).35
Likewise, the lack of functional rescue in older mutants was
not the result of low or absent transduction efficiency. When
incorporated into the rAAV5 vector, the PR2.1 promoter results in
specific expression of reporter gene in normal or CNGB3-mutant
L/M cones.10,36 Furthermore, quantitative real-time PCR (qRTPCR) analysis of hCNGB3 expression 18 to 46 weeks after treatment that resulted in no cone functional recovery showed high
expression levels (Figure 1b), and comparable with those previously reported for successfully treated younger eyes.10

Table 1 Treatment of CNGB3-mutant dogs

Dog ID/gender

M616/m

Age
(months)

14.3

Genotype

CNGB3−/−

Subretinal injection
rAAV5-PR2.1-hCNGB3

Cone
function

Tissue analyses
(weeks after
CNTF)

Eye

Intravitreal
injection

Vol (vg/ml)

ERG (weeks
after CNTF)a

R

CNTF

140 µl (4.02 × 1013)

0, 1, 6, 8.5

+

qRT-PCR (27)

L

PBS

160 µl (4.02 × 1013)

0, 1, 6, 8.5

−

qRT-PCR (27)

M617/m

14.3

CNGB3−/−

R

PBS

120 µl (4.02 × 1013)

0, 1, 6, 8.5, 13

−

qRT-PCR (27)

M621/f

15

CNGB3−/−

R

CNTF

140 µl (4.02 × 1013)

0, 1, 6

+

qRT-PCR (25)

L

PBS

140 µl (4.02 × 10 )

0, 1, 6

−

qRT-PCR (25)

M589/m

20.8

CNGB3−/−

L

CNTF

180 µl (1.02 × 1013)

0, 1, 5, 11

+

qRT-PCR (89)

M576/f

28.3

CNGB3

R

CNTF

L

PBS

R

GS83/f
GS112/f
GS115/f

42
16.3
16.3

−/−

CNGB3m/m
CNGB3m/m
CNGB3m/m

13

170 µl (1.17 × 10 )

1, 5

b

+

qRT-PCR (46)

170 µl (1.17 × 1013)

1, 5

−

qRT-PCR (46)

CNTF

200 µl (7.96 × 1011)

0, 1, 6, 10, 16

+

qRT-PCR (18)

L

PBS

200 µl (7.96 × 1011)

0, 1, 6, 10, 16

−

qRT-PCR (18)

R

CNTF

200 µl (7.96 × 1011)

0, 1, 6, 10, 16

+

IHC (18)

L

PBS

200 µl (7.96 × 1011)

0, 1, 6, 10, 16

−

IHC (18)

R

CNTF

200 µl (7.96 × 1011)

0, 1, 6, 10, 16

+

qRT-PCR (18)

13

L

PBS

200 µl (7.96 × 10 )

0, 1, 6, 10, 16

−

qRT-PCR (18)

GS87/mc

13.5

CNGB3m/m

R

No

150 µl (7.73 × 1012)

4, 44d

−

qRT-PCR (44)d

GS89/f

13.5

CNGB3

m/m

R

No

150 µl (7.73 × 10 )

4, 68

+

qRT-PCR (68)d

GS80/mc

16.5

CNGB3m/m

L

No

160 µl (9.43 × 1012)

4d

M635/f

13.3

CNGB3

R

CNTF

L

CNTF

R
L
R

c

M614/f
GS98/m

9.8
45.4

CNGB3

−/−

−/−

CNGB3

m/m

11

12

d

−

IHC (16)d

No

b

0, 1

+

qRT-PCR (1)

No

0, 1b

+

IHC (1)

CNTF

No

b

1, 5

+

qRT-PCR (94)

PBS

No

1, 5

−

qRT-PCR (94)

CNTF

No

2.5, 3.5, 4.5

+

IHC (7)

b

Gender: male (m), female (f); genotype, D262N missense mutation (CNGB3m/m), genomic deletion (CNGB3−/−); eye: right (R), left (L); intravitreal injection of either
CNTF (12 µg in 30 µl PBS) or PBS (30 µl); ERG, electroretinography; IHC, immunohistochemistry; qRT-PCR, quantitative real-time PCR; vg, vector genomes. aTime
points of recordable cone function are shown in boldface. bCone function was detectable in these eyes after CNTF administration alone (M635, M614, GS98), or
before therapeutic vector injection (M576; 1 week). cTimes are after subretinal injection with therapeutic vector. dDogs also included in previous publication.10
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Intravitreal CNTF enhances rAAV5-mediated cone
functional rescue in older mutant retinas
To determine if pretreatment with CNTF improved functional rescue in older retinas, we injected CNTF intravitreally 1 week before
rAAV5-PR2.1-hCNGB3 administration in 14.3- to 42-month-old
mutants, and assessed functional outcomes by recording the isolated cone electroretinogram (ERG) responses. All seven dogs
treated in this manner had a robust and stable recovery of cone
function detected by 4–5 (n = 4) and 7.5–9 (n = 3) weeks after
gene therapy (Figure 1a and Table 1). Expression of the hCNGB3
transgene in successfully treated (CNTF and therapeutic vector)
older mutant retinas was comparable with successfully treated
younger eyes,10 and to retinas pretreated with PBS that showed no
functional cone rescue (Figure 1b). Hence, the restoration of cone
function in older CNGB3-mutant dogs is not solely depend on the
expression of the hCNGB3 transgene mRNA.
We have not been able to determine the expression of hCNGB3
transgene product in treated retinas as multiple antibodies produced have not been specific. However, surrogate markers of
effective cone transduction, e.g., GNAT2, CNGA3, can be used.10
Baseline

CNTF

1 week

Intravitreal CNTF and reversible photoreceptor
deconstruction
To better understand the effect of CNTF in enhancing functional
rescue in CNGB3-mutant cones, we first examined the photoreceptor effects and potential signaling pathways involved in normal canine retinas (see Supplementary Table S1 for details of
procedures). Consistent with previous observations in rodents,30
intravitreal CNTF had a dramatic effect on retinal function, with
decreases in both rod- and cone-mediated ERG response amplitudes (Figure 3a). This effect was first noted at 3 days, peaked
at 1 week, and recovered to normal by 5 weeks after injection
(Figure 3b). The ERG effects corresponded temporally with

5 weeks

16 weeks

rAAV5-hCNGB3

CNTF &
rAAV5-hCNGB3
rAAV5-hCNGB3

PBS

b

4

Log (relative hCNGB3
gene expression)

a

In the normal retina, both show localization restricted to the
outer segments, whereas in mutants, the proteins are expressed
but delocalized from the cone outer segments.10,35,37 We find that
restored cone function in CNTF/rAAV5-treated CNGB3-mutant
adult retinas is associated with normal localization of both GNAT2
and CNGA3 in cone outer segments, but this is not found in PBS/
rAAV5-treated cones (Figure 1c).

PBS &
rAAV5-hCNGB3

3

2

1

10 µV

PBS &
rAAV5-hCNGB3

30 msec

c

wt

L/M

L/M

CNTF &
rAAV5-hCNGB3

ACHM

CNGA3

Merge

L/M

GNAT2

Merge

L/M

ACHM-PBS & rAAV5-hCNGB3

CNGA3

Merge

GNAT2

Merge

ACHM-CNTF & rAAV5-hCNGB3

L/M

CNGA3

Merge

L/M

CNGA3

Merge

L/M

GNAT2

Merge

L/M

GNAT2

Merge

Figure 1 Effect of intravitreal CNTF administration and subretinal rAAV5-PR2.1-hCNGB3 on the CNGB3-mutant retina. (a) Gene augmentation in a CNGB3−/−-mutant dog (28.3 months) rescues 29-Hz flicker cone responses when preceded by intravitreal CNTF injection (top row). No
rescue of cone function was achieved when intravitreal PBS was used before gene therapy (bottom row). The dashed lines indicate stimulus onset
and oblique arrows the individual cone-mediated flicker responses. (b) The relative amounts of retinal hCNGB3 mRNA expression were comparable
and not significantly different when subretinal rAAV injections were preceded by either intravitreal PBS (no cone function) or CNTF (cone function).
(c) Immunolabeling with CNGA3 and GNAT2 shows absence of cone outer segment labeling in untreated mutants (illustrated for a 10-month-old
CNGB3m/m retina) even though L/M-cone opsin label is present. With few exceptions (arrows) cone outer segments following the treatment with PBS
& rAAV5-PR2.1-hCNGB3 are also negative. Normal retinas and those treated with CNTF & rAAV5-PR2.1-hCNGB3 have normal outer segment immunolabeling. Calibration bar = 10 µm. ACHM, achromatopsia-affected; CNTF, ciliary neurotrophic factor; msec, milli second; wt, wild-type.
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a

L/M cones

S cones

− 26%*

− 27%**

742 ± 10

7,236 ± 427 5,296 ± 181
Area centralis

T

− 21%*

Area centralis

8,341 ± 332 6,600 ± 591

− 6%

− 8%

− 27%*

5,957 ± 480
5,590 ± 488

10,786 ± 741
9,977 ± 998

7,742 ± 34
5,663 ± 873

T − 17%**

− 43%** N

899 ± 25
746 ± 2.6

6,221 ± 439
3,551 ± 476

549 ± 75

− 3%
749 ± 9.2

725 ± 61

− 10%

− 28%**

1,320 ± 68
1,191 ± 29

969 ± 0.29
702 ± 7.3

− 37%** N
779 ± 14
494 ± 27

− 31%**

− 34%**

1,203 ± 0.55

6,793 ± 0.8 4,451 ± 31

836 ± 21

− 43%**

− 44%**

811 ± 1.12

3,783 ± 27 2,108 ± 339

464 ± 14

% Change
Wild-type

b

2 years

1 year
wt

ACHM (CNGB3−/−)

Achromatopsia

wt

ACHM (CNGB3 m/m)

4 years

7 years

ACHM (CNGB3 m/m)

ACHM (CNGB3−/−)

OS
IS

ONL

OPL

Figure 2 Changes in cones with age and disease progression. (a) Calculated loss of L/M- and S-cone densities at 1 year of age are shown separately for four quadrants based on cone counts from selected regions of retinal flat mounts from wild-type (wt) and CNGB3−/−-mutant dogs. The
decrease in cone density for both classes is most significant in the peripheral regions of the inferior, nasal, and superior quadrants. The loss is ≤10%
and not significant in the area centralis located temporal to the optic disc. (b) Compared with wt controls, mutant (ACHM) retinas show gradual loss
of cones (labeled red for human cone arrestin, hCAR), preceded by shortening and disruption of their inner and outer segments. There is migration
of hCAR-labeled cone nuclei into the subretinal space adjacent to the retinal pigment epithelium (arrows, ectopic cone nuclei). Cell nuclei are shown
in blue with DAPI. *P < 0.05, **P < 0.0001. Calibration bar = 20 µm. Dog fundus drawing reprinted with permission from Dr Kerry Ketring. IS, inner
segments; T, temporal; N, nasal; OS, outer segments; ONL, outer nuclear layer; OPL, outer plexiform layer.

changes in photoreceptor structure and gene product expression.
At 1 week, both rod and cone outer segments shortened dramatically throughout the retina. S-cones appeared more severely
affected at the 1-week time point as hardly any S-cone outer segments were identifiable (Figure 4). Electron microscopy demonstrated that, in addition to outer segment shortening, there was
membrane disorganization and vesiculation of both rod and cone
outer segments (Supplementary Figure S1). By 2 weeks, outer
segments were longer but appeared slightly disorganized, and
photoreceptors were normal 5 weeks after injection (Figure 4).
We then examined the gene expression levels of outer segment visual pigment proteins and CNG channel subunits of rods
and cones, and found a marked decrease in photoreceptor gene
expression 1 week following CNTF that appeared to fully recover
by 2 weeks (Figure 5a,b). With the exception of S-opsin expression which was ~0.1% of the biological control group, cone-specific gene expression decreased to ~24–39% and rod-specific gene
expression to ~14–19% at 1 week (Figure 5a,b).
We found no increased labeling of cells in normal and
CNGB3-mutant retinas for phosphohistone-H3 (PHH3),38 ruling out CNTF-induced cell proliferation. Furthermore, TUNEL
labeling38,39 was negative following CNTF treatment, emphasizing
that there was no cell death associated with treatment despite the
dramatic structural changes.
As the Jak/Stat pathway is presumably activated following treatment with CNTF29 in the Müller glia and photoreceptor cells that
1134

express the α-subunit of the CNTF receptor (CNTFRα40), we next
assessed this pathway. Both STAT1 and STAT3 mRNA expression
levels were elevated at 1 week, remained elevated at 2 weeks, and
returned to normal at 5 weeks (Figure 6a). Levels of phosphorylated STAT1 and STAT3 were elevated at 1 week, but by 2 weeks
had returned to baseline (pSTAT1) or remained slightly elevated
(pSTAT3) (Figure 6b,c). CNTF also led to upregulation of STAT1
expression at 1, 2, and 5 weeks (Figure 6b,c). In the retina, phosphorylated STAT was present in the vitreal margin of the inner
nuclear layer, and in photoreceptor cells. As with western blots,
peak expression was at 1 week, and decreased to control levels by 5
weeks (Figure 6d). These results show that the intravitreal injection
of CNTF in the normal canine retina results in activation of the Jak/
STAT pathway in photoreceptors and other inner nuclear layer cells.
In the mutant retina, surprisingly, we found that CNTF by
itself also induced a partial restoration of cone function in older
animals. One to 2.5 weeks after CNTF treatment, four of four
eyes had low amplitude cone flicker ERG responses with prolonged implicit times (Table 1 and Figures 1a and 7). This effect
was short-lived, and cone signals were lost after 5 weeks in the
absence of staged rAAV5-PR2.1-hCNGB3 treatment (Table 1 and
Figure 7).
In the dog, retinal development occurs postnatally with gradual maturation of ERG responses.41 A similar process occurs in
CNGB3 mutants, and immature, albeit abnormal, cone responses
are present only between 4 and 6 weeks of age before being
www.moleculartherapy.org vol. 21 no. 6 june 2013
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a

1 week

CNTF treatment
PBS treatment

2 weeks

5 weeks

Rod
X axis: 20 msec/div
Y axis: 20 µV/div

Mixed rod-cone

Cone, 1 Hz

Cone, 29 Hz

Relative amplitude

b

Mixed rod-cone b-wave

Rod b-wave

3

Cone—1 Hz b-wave

Cone—29 Hz b-wave

2
1
0

1 week 2 weeks
0

10

5 weeks
30

20

Days after CNTF injection

40

1 week 2 weeks
0

10

20

5 weeks
30

Days after CNTF injection

40

1 week 2 weeks
0

10

20

5 weeks
30

Days after CNTF injection

40

1 week 2 weeks
0

10

20

5 weeks
30

40

Days after CNTF injection

Figure 3 Intravitreal CNTF results in a transient decrease in rod- and cone-mediated ERG responses in normal retina. (a) In comparison with
intravitreal PBS that had no effect on the ERG (gray traces), intravitreal CNTF (black traces) markedly reduced rod and cone amplitudes. Retinal function was most severely affected at 1 week, partially restored at 2 weeks, and returned to normal at 5 weeks after injection. (b) Scatterplots showing
relative ERG amplitudes over time after injection (relative amplitude = amplitude CNTF-treated eye/amplitude contralateral PBS-treated eye). The
depression of retinal responses was first noted at 3 days after CNTF injection, peaked at 1 week, and recovered to normal by 5 weeks. The linear traces
connect the median values between each time point. CNTF, ciliary neurotrophic factor; msec, milli second.
Control

1 week

2 weeks

5 weeks

hCAR

L/M

S

Rho

Figure 4 Intravitreal CNTF leads to a transient shortening of photoreceptor outer segments in the normal canine retina. Compared with
PBS-injected control eyes, CNTF causes a uniform shortening of cone (hCAR) and rod (Rho) outer segments at 1 week. This effect was more dramatic
for the S-cones (S) than for the L/M-cones (L/M) since hardly any labeled S-cone outer segments could be identified at 1 week. At 2 weeks, the photoreceptors appear partially recovered, and are normal at 5 weeks. Cell nuclei are shown in blue with DAPI. Calibration bar = 20 µm. CNTF, ciliary
neurotrophic factor; hCAR, human cone arrestin; INL, inner nuclear layer; IS, inner segments; L/M, L/M-opsin; ONL, outer nuclear layer; OPL, outer
plexiform layer; OS, outer segments; S, S-opsin.
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a

Cone genes
PBS
CNTF

1.4
Relative expression

1.2
1.0
0.8
0.6
0.4
0.2
0

L/M-opsin S-opsin CNGA3 CNGB3

L/M-opsin S-opsin CNGA3 CNGB3 L/M-opsin S-opsin CNGA3 CNGB3

1 week

b

2 weeks

5 weeks

Rod genes
1.8

Relative expression

1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0

Rho

CNGA1
1 week

CNGB1

Rho

CNGA1
2 weeks

CNGB1

Rho

CNGA1
5 weeks

CNGB1

Figure 5 Intravitreal CNTF leads to a transient reduction of photoreceptor-specific gene expression. Relative (a) cone and (b) rod gene expression measured by qRT-PCR is shown following either intravitreal CNTF or PBS injection compared with a normal biologic control group (n = 3). CNTF
treatment results in gene expression levels that are ~14–39% of normal for most genes at 1 week. S-cone opsin levels were affected to the greatest
extent (~0.1% of normal). Expression was comparable with PBS injected eyes by 2 and 5 weeks. CNTF, ciliary neurotrophic factor; qRT-PCR, quantitative real-time PCR.

permanently lost (Figure 7). In adult mutants, CNTF treatment
resulted in cone responses that were similar to, but of lower amplitude, than those recorded from mutant retinas in the early phases
of postnatal differentiation. We posit that this transient appearance of cone function occurs from partially functional CNGA3
homotetramer channels that form following the regrowth of cone
outer segments after CNTF administration.42,43 Indeed, the immunohistochemical evaluation of a CNGB3-mutant retina with partially restored cone-mediated function 1 week following CNTF
treatment (M635 in Table 1) revealed restoration of weak expression of both CNGA3 and GNAT2 in some of the deconstructed
cone outer segments (Supplementary Figure S2).

DISCUSSION

Our present work clearly shows that a combined staged therapy
of CNTF and rAAV5-PR2.1-hCNGB3 successfully restores cone
function in two canine models of CNGB3-achromatopsia at older
ages (14–42 months) when, in the majority of cases, gene augmentation therapy alone cannot. Our data thus provide proof of
concept for potential CNTF and gene augmentation combination therapy for restoring cone function in older patients with
CNGB3-achromatopsia if standard gene augmentation therapy is
not effective. In addition, understanding the mechanistic basis for
the CNTF effect will provide essential insights for future understanding of the disease progression in CNGB3-achromatopsia,
and the mechanism that mediates the CNG channel assembly and
targeting to the cone outer segments.
Although only ~5% of the photoreceptors in the human retina are cones,44 they are essential for color vision, central visual
1136

acuity and day vision, and loss of their function leads to severe
visual dysfunction and impaired quality of life. To this end, we
have selected achromatopsia, an autosomal-recessive cone visual
function disorder, as a test platform to develop gene therapy that
broadly may be applicable to cone-specific diseases. The majority
of human achromatopsia patients have a channelopathy caused by
mutations of either the α- or β-subunits of the cone CNG channels, responsible for the last step in phototransduction.25,26,42,45 The
present studies were carried out in canine models with either a
missense mutation in exon 6 or a genomic deletion of CNGB3,27
both of which are functional nulls based on disease phenotype
and response to therapy.10 As in human patients with achromatopsia,46 the loss of the non-functional cones in canine CNGB3achromatopsia is slow, and adequate numbers of cones are present,
even at advanced ages, to permit functional recovery provided
treatment is effective. Thus, preclinical studies, including our
present work on the CNGB3-achromatopsia models, may have
broad implication not only on treating CNGB3-achromatopsia in
humans, but also other cone-specific diseases.
Proof of principle studies have demonstrated successful conedirected therapy in mouse and canine achromatopsia models
(mouse: GNAT2,12 CNGA3,13,15 and CNGB3;14 dog: CNGB3).10
However, despite the very slow cone loss in CNGB3-mutant dogs
and the successful treatment by gene augmentation in young animals, treatment with the same therapeutic vector is ineffective in
animals >1 year.10 Carvalho and colleagues have demonstrated
a small age effect when assessing outcome of gene therapy in
CNGB3-mutant mice; there was both a decrease in visual function and cone ERG amplitude recovery with increasing age at the
www.moleculartherapy.org vol. 21 no. 6 june 2013
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Figure 6 Intravitreal CNTF injection activates the Jak/Stat pathway in the normal canine retina. (a) Compared with intravitreal PBS, both STAT1
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time of treatment.14 Similar to the CNGB3-mutant dogs,10 cone
function was restored in mice up to 6 months of age with gene
therapy alone.14 Older mice were not treated, and visual acuity
could not be improved in the 6-month old animals.14 Our present work demonstrates that the lack of functional restoration in
older animals is not due to the loss of cones. Neither is it because
of lack of therapeutic transgene expression, indicating that viral
vector tropism and transduction efficiency are not limiting factors (Komáromy and colleagues10 and present study). Instead, our
results point to an age-related defect in the ability of the hCNGB3
transgene protein to either assemble with CNGA3 or promote
localization of the heterodimeric complexes to the outer segment.
Alternatively, the deterioration of cone outer segments found in
Molecular Therapy vol. 21 no. 6 june 2013

some older mutant retinas indicates that those cells are in the early
stages of degeneration, and not capable of assembling structural
components of the outer segment.33 The two explanations are not
mutually exclusive.
As a means of developing a treatment for older animals that
had adequate numbers of viable cones whose function potentially could be rescued, we used intravitreal bolus administration of CNTF to transiently deconstruct the mutant cones before
gene transfer. We reasoned that such treatment could potentially
“rejuvenate” the cone outer segment, allowing for proper assembly of the membrane subunits of the CNG channel, thereby
permitting functional recovery following therapy. In support,
intravitreal bolus administration of CNTF successfully modified
1137
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Figure 7 Full-field ERGs recorded from developing CNGB3 mutants, and adult CNGB3 mutants treated with CNTF. (a) Responses recorded from
a mature wild-type dog for comparison. (b) Responses were comparable during retinal development between the dogs with the genomic deletion
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cone cells in the retinas of older mutants which then functioned,
albeit abnormally, like those of younger mutants. After rAAVPR2.1-hCNGB3 treatment, assembled channels were correctly
targeted to the outer segment, leading to successful functional
recovery. We posit that deconstruction induced by CNTF, either
concurrent with or after vector administration, is likely to also
lead to recovery of cone function. This hypothesis needs to be
tested experimentally, and investigations are currently underway
1138

to establish the most effective treatment method. Although our
current data suggest that the transient photoreceptor deconstruction may be mediated by the Jak/Stat pathway, the exact
mechanism leading to the restoration of cone function with
CNTF treatment in the older animals requires more investigation. As an example, the use of CNTF could be combined with
Jak or Stat inhibitors to support or exclude the Jak/Stat pathway
as a mediator of this finding.
www.moleculartherapy.org vol. 21 no. 6 june 2013

© The American Society of Gene & Cell Therapy

The partially and transiently restored cone ERG in some of the
CNGB3-mutant canine retinas with weak expression of CNGA3
and GNAT2 following CNTF treatment indicates that the phototransduction components were at least temporarily reassembled
in some of the regenerated cone outer segments, providing the
optimal conditions for successful outcome for gene augmentation.
Because of the design of our ERG testing protocol, and the equal
deconstruction of rod and cone outer segments, it is unlikely that
the observed photopic responses in eyes treated only with CNTF
were rod mediated rather than cone mediated. The light adaptation levels were more than sufficient to suppress rod signals, and
the flash frequencies used for 29-Hz flicker stimuli and for averaging of single responses were too fast for rods.
The concept of combining retinal gene augmentation therapy with the application of neurotrophic factors to enhance
treatment outcome has been used previously as a means of
delaying photoreceptor cell death prior therapeutic transgene
expression.47 However, deconstructing and regenerating the
photoreceptor outer segments in preparation for gene augmentation is a novel concept that may complement more traditional
approaches when remaining photoreceptors, either rods or
cones, are refractory to therapy. Future studies are needed to
examine the broader applicability and molecular mechanisms
of CNTF-induced photoreceptor deconstruction, and evaluate
if it allows for improvement of gene therapy outcomes in other
inherited photoreceptor-specific diseases. As CNTF delivery
via Encapsulated Cell Technology implants have been tested
experimentally in animals48 and are undergoing clinical trials
for age-related macular degeneration and retinitis pigmentosa,
it is possible that such Encapsulated Cell Technology implants
combined with therapeutic vectors may further facilitate translational applications.29
In summary, we have shown that a combination therapy of
CNTF and gene augmentation can successfully restore cone function in two CNGB3-achromatopsia dog models when treated
at older ages when gene therapy alone is ineffective. This novel
approach could also help in the treatment of other inherited
photoreceptor-specific diseases. Further studies are needed
to inform on the molecular mechanism that underlying the
effects of CNTF in facilitating gene augmentation therapy for
CNGB3-achromatopsia.

MATERIALS AND METHODS

Animals. Achromatopsia-affected dogs were homozygous for either a

CNGB3 genomic deletion (CNGB3−/−; n = 7) or a D262N missense mutation (CNGB3m/m; n = 4), both of which result in an identical phenotype.10,27
To evaluate the effect of intravitreal CNTF injection on the normal retina,
12 unaffected dogs were used. At the conclusion of the study, the dogs were
euthanatized with an overdose of euthanasia solution (Euthasol; Virbac,
Fort Worth, TX), and the eyes enucleated for molecular and histologic
studies. In addition, eyes were collected from seven mutant dogs and six
normal controls to determine cone densities and topographic distribution with disease progression on retinal flat mounts, and for comparison
of immunohistochemical labeling. Retinal RNA was extracted from the
eyes of three additional normal, untreated dogs as biologic controls for
analysis of the qRT-PCR data. All the dogs were part of a research colony
maintained at the Retinal Disease Studies Facility (Kennett Square, PA)
and supported by National Eye Institute, NIH (EY-06855) and Foundation
Fighting Blindness Center grants. The studies were done in accordance
Molecular Therapy vol. 21 no. 6 june 2013
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with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, and approved by the University of Pennsylvania IACUC.
Recombinant CNTF protein. Recombinant protein was generated by clon-

ing the human CNTF cDNA ORF into expression vector pQE30 (Qiagen,
Valencia, CA), and expressed in E. coli (XL-blue; Stratagene, La Jolla, CA)
as previously described.30 The CNTF solution was filtered (Millex-GV 0.22
µm filter unit; Millipore, Carrigtwohill, Ireland) and stored in 30 µl PBS
aliquots at −80 °C, each containing 12 µg of CNTF. For control injections,
sterile 30-µl PBS aliquots were stored at −80 °C.
Vector. The therapeutic vector, rAAV5-PR2.1-hCNGB3, was constructed,
titered, and purified as previously described.10 This vector provides the
most robust rescue of cone function in achromatopsia, but only targets the
canine L/M-cones.10,36 Initially, the vector was injected at concentrations
of 1.02–4.02 × 1013 vector genomes/ml (vg/ml). Because of mild multifocal
chorioretinitis and slight retinal thinning in the treatment area, an indication of vector-associated retinal toxicity,49 the concentration was lowered
to 7.96 × 1011 vg/ml and all adverse effects prevented.
Intraocular injections. Intravitreal injection of either CNTF (12 µg of

CNTF in 30 µl of PBS) or PBS (30 µl) was performed under general anesthesia (Table 1 and Supplementary Table S1). On the basis of the vitreous volume of adult dogs (2.5–3.0 ml50), the injected dose of CNTF was
~ 4–5 µg/ml. In 14 eyes of 8 dogs, the intravitreal injection of CNTF or
PBS was followed 1 week later by the subretinal administration of rAAV5PR2.1-hCNGB3 vector (Table 1). Between 120 and 200 µl of vector was
injected with a RetinaJect subretinal injector (SurModics, Eden Prairie,
MN) through a transvitreal approach as previously described.10,36 The area
treated was in the tapetal zone superior to the optic disc, a region with
higher cone density,34 and was ~25% of the photoreceptor surface area.
Immediately following surgery, the retinal location and extent of the subretinal blebs were documented by fundus drawings for reference in the
morphologic studies. Flattening of the subretinal bleb and retinal reattachment occurred within 24–36 hours.
Electroretinography. Standard Ganzfeld scotopic and photopic ERGs were

recorded from anesthetized dogs using a modified Ganzfeld dome fitted
with the LED stimuli of a ColorDome stimulator (Diagnosys LLC, Lowell,
MA).10 Rod and mixed rod-cone–mediated responses were recorded after
20 minutes of dark adaptation with single white flash stimuli of increasing
intensities (from 0.000577 to 10.26 cd.seconds/m2). Following 10 minutes
of light adaptation (34.26 cd/m2), cone-mediated signals were recorded
to 1-Hz single flash (from 0.00577 to 10.26 cd.seconds/m2) and 29.41-Hz
flicker (from 0.00577 to 5.77 cd.seconds/m2) stimuli. The combination of
light adaptation with short flash intervals led to saturation of rods and isolation of pure cone-mediated responses. Except for the brighter scotopic
light stimuli (≥ 0.577 cd.seconds/m2) multiple responses were averaged.
Retinal morphology and immunohistochemistry. Enucleated eyes were

fixed for 3 hours in 4% paraformaldehyde followed by 21 hours in 2% paraformaldehyde, both in 0.1 mol/l PBS at 4 °C. Subsequently, the tissue was
processed for embedding in optimal cutting temperature medium.11,39,40,49
Retinas that were only treated by intravitreal CNTF or PBS injections were
sectioned in the four cardinal meridians through the optic nerve head.
Retinas that underwent subretinal injections were oriented and sectioned
based on the location of the treated area to compare treated and untreated
regions. Cryosections of 10µm were examined by immunohistochemistry
for protein expression and H&E staining. The primary antibodies and cell
markers used are detailed in Supplementary Table S2. Six different custom made canine CNGB3 antibodies were made, but lacked specificity for
either the canine or human proteins even though they shared sequence
homology for the targeted epitopes. Alexa Fluor–labeled goat antirabbit
IgG, donkey antigoat IgG, chicken antimouse IgG, or donkey antimouse
IgG (1:200; Molecular Probes, Eugene, OR) were used as secondary
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antibody. For pSTAT1 and pSTAT3 immunohistochemistry, heat-induced
epitope retrieval was done before overnight incubation with primary antibodies. HRP-labeled goat antirabbit secondary antibodies were used in
combination with the ABC immunoenzymatic detection method. With
fluorescence immunohistochemistry, DAPI stain was used as a nuclear
stain. The In Situ Cell Death Detection kit (Roche Applied Science,
Indianapolis, IN) was used to visualize apoptotic nuclei following CNTF
injection by TUNEL (terminal deoxynucleotidyl transferase-mediated
biotinylated UTP nick end labeling). Sections were examined with a Zeiss
Axioplan microscope (Carl Zeiss Meditec, Dublin, CA), images were digitally captured (Spot 4.0 camera; Diagnostic Instruments, Sterling Heights,
MI) and imported into a graphics program (Photoshop; Adobe, Mountain
View, CA) for display. Selected tissues (Figure 1c and Supplementary
Figure S2) were imaged by laser scanning confocal microscopy (Olympus
FluoView FV1000; Olympus America, Center Valley, PA).
The effect of intravitreal delivery of CNTF or PBS on photoreceptor
ultrastructure was evaluated by electron microscopy 1 week after injection
in a normal dog. Immediately after enucleation, the posterior segments
were isolated and fixed, using a triple fixative protocol as previously
reported.41 The posterior segments were then trimmed, dehydrated, and
embedded in epoxy resin (PolyBed 812; Polysciences, Warrington, PA).
Thin sections (70–80 nm) were cut and picked up on Formvar coated
copper grids, stained with uranyl acetate and lead citrate, and examined
with a JEOL 1010 electron microscope (JEOL USA, Peabody, MA) fitted
with a Hamamatsu digital camera (Hamamatsu Corporation, Bridgewater,
NJ) and AMT Advantage image capture software (Advanced Microscopy
Techniques, Corp., Woburn, MA).
Mapping of cone photoreceptors in CNGB3-achromatopsia. To determine the cone density in mutant retinas, selected retinal regions were
examined in 2 affected and 3 control dogs at 1 year of age. Eyes were collected following euthanasia, fixed between 20 min and 1 h in 4% paraformaldehyde in 0.1 mol/l phosphate-buffered saline (PBS) at 4 °C, and each
retina divided into quadrants along the horizontal and vertical meridians.
Beginning 2 mm from the optic disc, two consecutive 4-mm circular retinal punches without retinal pigment epithelium were collected with a disposable biopsy punch from each quadrant; these were fixed for 2 hours in
2% paraformaldehyde in 0.1 mol/l PBS and then stored in PBS at 4 °C for
immunolabeling with antibodies for S- and L/M-cone opsin and hCAR
(Supplementary Table S2). Alexa Fluor–labeled goat antirabbit IgG, donkey antigoat IgG, or chicken antirabbit IgG (1:200; Molecular Probes)
secondary antibodies were used. The cone subclasses were identified by
double labeling with either S- or L/M- and hCAR-antibodies. Doublelabeled retinal patches were flat mounted on a glass slide in 0.1 mol/l PBS
with the photoreceptor outer segments pointing up, cover slipped, and
sealed with nail polish.
The immunolabeled cone subclasses were imaged within a 2-mm
diameter circle centered inside each 4-mm retinal trephine using the same
Zeiss Axioplan microscope (Carl Zeiss Meditec) and Spot 4.0 camera
(Diagnostic Instruments) as described above. The labeled cone outer
segments were manually marked on the digital images using Photoshop
software (Adobe) and counted with image analysis software (MCID
Analysis version 7.0 grain counting software; Interfocus, Linton, UK).
qRT-PCR analysis of retinal gene expression. Whole retinas were isolated from the eyecups within 1–2 minutes of euthanasia, flash frozen in
liquid nitrogen, and stored at −80 °C until used. The retinal tissue was
homogenized, and total RNA extracted with TRIzol Reagent (Invitrogen,
Life Technologies, Carlsbad, CA). RNA concentrations were determined
using an ND1000 spectrophotometer (Nanodrop Products, Wilmington,
DE). Retinal cDNA was synthesized by reverse transcription using the
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life
Technologies, Carlsbad, CA) and the manufacturer’s instructions. qRTPCR was done as previously described using primers and TaqMan MGB
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probes designed for the hCNGB3 transgene, and canine-specific probes for
cCNGA3, cCNGB3, cL/M-opsin, cS-opsin, cCNGA1, cCNGB1, and cRHO
(Supplementary Table S3).10 TaqMan expression assays were commercially
available for STAT1 and STAT3 mRNA (Cf02662970_m1 and Cf02666647_
m1; Applied Biosystems). Relative gene expression for each gene compared
with the 18S rRNA product (Hs99999901_s1; Applied Biosystems) was calculated as 1/[2^(CtGene − Ct18S)]. Only for the hCNGB3 transgene in retinas
injected with rAAV5-PR2.1-hCNGB3 was relative gene expression used to
directly compare CNTF and PBS-treated eyes by unpaired t-test. For all the
other genes, the ratio of relative gene expressions was calculated between
the treated eye and an untreated biological control group using the ∆∆CT
method.38 Any ratio considerably different from 1 was relevant and indicated either an increase (>1) or decrease (<1) of gene expression. Because
of the small group size for each time point in normal animals undergoing
intravitreal injections alone, comparisons were made by descriptive statistics. In contrast, the sample sizes were larger for rAAV5-PR2.1-hCNGB3treated eyes, allowing the comparison of these gene expression ratios
between PBS- and CNTF-injected eyes by one-way analysis of variance.
Western blotting. Retinal samples were harvested as described for qRT-

PCR analysis and frozen at −80 °C. The retinas were homogenized in a
modified RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 158 mmol/l NaCl, and 10 mmol/l Tris) containing a protease inhibitor cocktail (Complete-EDTA; Roche Diagnostics, Indianapolis, IN), followed by sonication on ice. The homogenate was centrifuged at 13,000g for
15 minutes at 4 °C, and the supernatant containing the proteins was collected. Total protein levels were determined by the Bradford method (ABC
protein assay; Bio-Rad, Hercules, CA). For western blot analysis, 10 µg of
protein were loaded onto each lane. Membranes were blocked for 1 hour at
4 °C (Blocking buffer; Li-Cor Biosciences, Lincoln, NE), and incubated for
1.5 hours at room temperature in primary antibodies pSTAT1 or pSTAT3
and actin to control for equal loading of each well (Supplementary
Table S2). pSTAT1 and pSTAT3 antibodies were detected with a near
infrared fluorescent goat antirabbit secondary antibody (IRDye 800 CW
goat antirabbit IgG; Li-Cor Biosciences), and STAT1 and actin antibodies
with a goat antimouse antibody (IRDye 680 LT goat antimouse IgG; Li-Cor
Biosciences) diluted to 1:15,000 for 1 hour at room temperature. The bands
were quantified by densitometry using Odyssey infrared imaging system
software (Odyssey version 2.1; Li-Cor Biosciences). Detection of STAT3
levels was performed on a separate blot using the enhanced chemiluminescence technique as we were unsuccessful in detecting both pSTAT3 and
STAT3 antibodies with the Odyssey technique on the same blot. Levels
of STAT3 and pSTAT3 were normalized to actin before calculating the
pSTAT3/STAT3 ratio.

SUPPLEMENTARY MATERIAL
Figure S1. Electron micrographs of normal canine retinas 1 week following intravitreal injection of PBS or CNTF.
Figure S2. Partial restoration of CNGA3 and GNAT2 protein localization in the CNGB3-mutant retina 1 week following intravitreal CNTF
injection.
Table S1. Intravitreal CNTF injections in normal dogs.
Table S2. Antibodies and reagents used for immunohistochemistry
and western blotting.
Table S3. Primers and probes for qRT-PCR and exon junction crossed
by PCR product.
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